Shares of Cardiol Therapeutics Inc. (TSE:CRDL – Get Free Report) traded up 1.3% during trading on Thursday . The stock traded as high as C$1.56 and last traded at C$1.51. Approximately 48,612 shares changed hands during mid-day trading, a decline of 50% from the average session volume of 97,890 shares. The stock had previously closed at C$1.49.
Cardiol Therapeutics Trading Up 1.3%
The company has a market cap of C$174.06 million, a PE ratio of -3.87 and a beta of 0.37. The business has a 50 day simple moving average of C$1.74 and a two-hundred day simple moving average of C$1.56. The company has a current ratio of 4.39, a quick ratio of 6.84 and a debt-to-equity ratio of 0.48.
Cardiol Therapeutics (TSE:CRDL – Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported C($0.10) earnings per share (EPS) for the quarter. On average, analysts forecast that Cardiol Therapeutics Inc. will post -0.49 EPS for the current fiscal year.
Cardiol Therapeutics Company Profile
Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.
Featured Articles
- Five stocks we like better than Cardiol Therapeutics
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
